Schroders Capital, Atlas Venture and Forbion led a $141m Series B funding round in AAVantgarde Bio.

Schroders Capital, a multinational asset management company, Atlas Venture, a venture capital fund specializing in early-stage industrial technology, and Forbion, a global venture capital firm with a focus on the life sciences and a growing strategy in the bioeconomy, led a $141m Series B funding round in AAVantgarde Bio, a clinical-stage Italian biotechnology company, with participation from Amgen Ventures, Athos KG, CDP Venture Capital through its Large Ventures Fund, Columbia IMC, Neva SGR, Sixty Degree Capital, XGen Venture, Willett Advisors, Longwood Fund and Sofinnova Partners. “This investment is a strong endorsement of our team, our science, and two clinical IRD programs,” Natalia Misciattelli, AAVantgarde Bio CEO.